Jump to main content
Jump to site search


Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

Author affiliations

Abstract

MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1). Immunological results indicate that the glycosylated tricomponent vaccine candidate has elicited both humoral and cellular immune responses. The induced antibodies could effectively bind to MCF-7. Furthermore, the vaccine exhibited an obvious reduction in tumour burden.

Graphical abstract: Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 03 May 2019, accepted on 10 Jul 2019 and first published on 12 Jul 2019


Article type: Research Article
DOI: 10.1039/C9MD00254E
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy

    M. Li, Z. Wang, B. Yan, X. Yin, Y. Zhao, F. Yu, M. Meng, Y. Liu and W. Zhao, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00254E

Search articles by author

Spotlight

Advertisements